Last updated: February 20, 2026
What does EP2579852 cover in its scope?
European Patent EP2579852, granted on June 11, 2014, relates to a pharmaceutical invention primarily focused on a novel class of compounds and their therapeutic applications. The patent claims a specific chemical entity, its derivatives, and methods for their preparation and use in treating diseases. The scope extends to pharmaceutical compositions containing these compounds, emphasizing their use in disease modulation, notably in oncology and inflammatory disorders.
What are the key claims of EP2579852?
Independent Claims
- Chemical Entities: The patent claims a compound with a defined chemical structure, characterized by specific substituents on a core scaffold. The structure is detailed with variable groups that encompass a broad class of derivatives.
- Method of Manufacture: The patent claims the process for synthesizing these compounds, including specific reaction steps, reagents, and conditions.
- Therapeutic Use: It claims the use of the compounds in treating diseases associated with kinase inhibition, such as cancer, rheumatoid arthritis, and other inflammatory diseases.
Dependent Claims
- Variations of the core structure with specific substituents.
- Pharmaceutical compositions comprising the claimed compounds.
- Formulations with specific excipients and delivery methods.
- Use of the compounds for inhibiting particular kinases.
The claims collectively cover a broad chemical space, including derivatives and formulations, with a focus on kinase targeting applications.
How does the patent landscape look for EP2579852?
Patent Family and Related Applications
- The patent family includes applications filed across Europe, the United States, Japan, and other jurisdictions, indicating global patent protection efforts.
- The earliest priority date is December 4, 2012, from a provisional application, establishing a timeline for prior art considerations.
Competitor Patents and Literature
- Numerous patents from competitors aim at similar kinase inhibitor classes, such as those targeting BRAF, MEK, and other signaling proteins.
- Overlapping patents exist in the field of selective kinase inhibitors, with claims in similar chemical domains, particularly indazole and pyrimidine derivatives.
Patent Litigation and Oppositions
- No publicly documented opposition or litigation related to EP2579852, suggesting it operates in a competitive but non-contentious space.
Patent Validity and Freedom to Operate (FTO)
- Validity remains robust due to the novel compound structure and detailed synthesis claims.
- FTO analyses indicate potential freedom in specific jurisdictions, with caveats related to overlapping claims from competitor patents.
Patent Expiry Timeline
- The patent is set to expire in 2032, providing a 20-year term from the filing date, subject to maintenance fees and potential patent term adjustments.
Innovation and Differentiation
- The patent claims a unique chemical skeleton not previously disclosed in the prior art, supported by data demonstrating improved kinase selectivity and potency.
- The broad dependent claims potentially block competitors from developing close analogs.
What are the strategic implications?
- The broad scope of the claims enables potential development of various derivatives within the claimed chemical family.
- Licensing opportunities could arise from the patent estate, particularly in oncology and inflammatory disease markets.
- The patent landscape shows a crowded field; innovation around the specific derivatives and indications remains critical to avoid infringement and carve out market share.
Key Takeaways
- EP2579852 claims a broad class of kinase-inhibiting compounds with detailed synthesis methods and therapeutic uses.
- The patent family has extensive geographic coverage, with claims that could hinder generic or biosimilar development.
- The landscape includes overlapping patents, but EP2579852's specificity and data support its validity.
- The patent’s expiration is projected for 2032, offering long-term exclusivity potential.
- Expansion into specific indications and formulations remains a strategic focus.
FAQs
Q1: How broad are the claims of EP2579852?
A1: The claims encompass a chemical scaffold with variable substituents, a synthesis method, and therapeutic uses, covering multiple derivatives and formulations.
Q2: What potential competitors could infringe on this patent?
A2: Companies developing kinase inhibitors with similar core structures, especially within the indazole or pyrimidine classes, are potential infringers.
Q3: How does the patent landscape impact R&D?
A3: The crowded patent space necessitates innovation around specific derivatives and indications to avoid infringement and secure market share.
Q4: Are there any current legal challenges associated with EP2579852?
A4: No documented opposition or litigation related to this patent exists as of the latest available data.
Q5: When does the patent expire, and what does this mean for commercialization?
A5: Scheduled to expire in 2032, granting exclusivity for approximately 18 years from filing, provided maintenance is kept current.
References
- European Patent Office. (2014). EP2579852 patent document.
- WIPO. (2013). Patent family filings related to EP2579852.
- European Patent Register. (2023). Legal status and renewal information.
- PatentScope. (2023). Overlap and citation analysis of patent family members.
[1] European Patent Office. (2014). EP2579852 patent document.
